ASCO 2024: Latest Data in Melanoma

home / post-conference-perspectives / asco-2024-latest-data-in-melanoma

Evan J. Lipson, MD, from Johns Hopkins University School of Medicine contributes key updates in melanoma treatment presented at ASCO 2024 in Chicago, Illinois.

Episodes

July 10th 2024EP. 1: ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

July 10th 2024EP. 2: Key Findings from the NADINA Trial at ASCO 2024

Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.

July 10th 2024EP. 3: ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.

July 13th 2024EP. 4: ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

Dr Lipson provides insights surrounding combination therapies in melanoma management.

July 13th 2024EP. 5: Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.

July 29th 2024EP. 6: ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

July 29th 2024EP. 7: Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions